Trukhin, Dmytro
Poddubskaya, Elena
Andric, Zoran
Makharadze, Tamta
Bellala, Ravi Shankar
Charoentum, Chaiyut
Yañez Ruiz, Eduardo P.
Fulop, Andrea
Hyder Ali, Irfhan Ali
Syrigos, Kostas
Katgi, Nuran
Lopez Chuken, Yamil Alonso
Rumyana, Ilieva
Reyes-Igama, Jasmin
Costamilan, Rita de Cassia
Del Campo García, Ana http://orcid.org/0000-0003-2709-5583
Florez, Amalia
Paravisini, Alexandra
Millan, Susana
de Lima Araujo, Luiz Henrique
de Oliveira Ferreira, Carla Maria
Pinczowski, Helio
Fernandes Monteiro, Maria Marcela
Dudov, Assen
Syrova, Janeta
Orlandi Jorquera, Francisco Javier
Gallardo Arenada, Carlos Eduardo
Caglevic Medina, Christian Lorenzo
Giorgadze, Davit
Mchedlidze, Nino
Kuchava, Vladimer
Melkadze, Tamar
Matitashvili, Amiran
Chikhladze, Nana
Samantas, Epaminodas
Kontakiotis, Theodoros
Balint, Beatrix
Medgyasszay, Balazs
Csanky, Eszter
Bondarde, Shailesh Arjun
Goyal, Lovenish
Sharma, Ajay
Balan, Baijumon
Mohapatra, Prabrajya Narayan
Patel, Kaushalkumar Babubhai
Hingmire, Sachin Sharadchandra
Shah, Mithun Satish
Jain, Kartikeya
Agrawal, Ashish
Kumbhaj, Prashant
Mukhopadhyay, Asis
Khoueiry, Paul
Yusak, Suhana
Pang, Yong Kek
Jye, Voon Pei
Yehgambaram, Prathepamalar
Ismail, Fuad bin
Appalanaido, Gokula Kumar
Barron Barron, Feliciano
Uy, Ma. Noemi
Martinez-Lapus, Felycette Gay
Tamayo, Maria Belen
Sandoval-Tan, Jennifer
Osorio Sanchez, Jamela Anne
Galvez, Christina G.
Contreras-Tolentino, Josephine
Ledin, Evgeny
Stroyakovskiy, Daniil
Kudryavtsev, Igor
Vladimirov, Vladimir
Gotovkin, Evgeniy
Shomova, Marina
Mukhametshina, Guzel
Lifirenko, Igor
Karaseva, Nina
Nechaeva, Marina
Tarasova, Anna
Luft, Alexander
Kuzina, Lyudmila
Petrovic, Marina
Rancic, Milan
Zaric, Borjan
Buranachokphaisan, Manoch
Geater, Sarayut Lucien
Tharavichitkul, Ekkapong
Gumus, Mahmut
Bondarenko, Igor
Shparyk, Yaroslav
Shevnia, Serhii
Lytvyn, Iryna
Kolesnik, Oleksii
Hotko, Yevhen
Sinielnikov, Ivan
Adamchuk, Hryhoriy
Ursol, Grygorii
Ivashchuk, Oleksandr
Ostapenko, Yuriy
Popovska, Tetiana
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)
https://doi.org/10.1007/s40259-021-00483-w
Funding for this research was provided by:
mAbxience Research SL
Article History
Accepted: 20 April 2021
First Online: 29 April 2021
Declarations
:
: The study was supported by mAbxience Research SL. Employees of the sponsor had a role in study design, data analysis and manuscript preparation. Employees of the funder had no role in data collection.
: SM, AP, AF and ADCG are employees at mAbxience Research SL.All the other authors declared that they have no conflicts of interest.
: The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: The study was conducted in accordance with the Declaration of Helsinki, the International Council for Harmonization Good Clinical Practice (ICH-GCP) guidelines and the appropriate regulatory requirements in the countries where the study was conducted. Ethical approval was sought and granted for each center. The protocol, its amendments and informed consent documentation were reviewed and approved by the institutional review board(s) or independent ethics committee(s) at each center.
: All patients signed an Institutional Review Board/Independent Ethics Committee-approved informed consent form before any study-specific procedures were performed.
: Not applicable.
: SM and AP were involved in the conception and design of the study. DT, EP, ZA, TM, FJOJ, BRS, CC, AF, HAIA, KS, NK, IR, FB, JI, PK and RDCC were involved in the provision of study material and patients and acquisition of data. SM, AP, AF and ADCG did the analysis and/or interpretation of data. All authors wrote the report and/or revised it critically for important intellectual content. All authors approved the final version.